Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic
March 17 2020 - 5:21PM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated
weight loss solutions company commercializing the first and only
FDA-approved swallowable, gas-filled intragastric balloon system
for the treatment of obesity, announces that it has
temporarily suspended sales of its novel weight loss treatment to
new patients at its existing retail treatment centers in San Diego
and Orange County, California as a precaution against the spread of
the coronavirus (COVID-19). The retail treatment centers will
continue to fully treat and care for patients already in treatment
with the Obalon Balloon System, and non-essential personnel will
work remotely.
“The safety, health and well-being of our patients, employees
and providers remain our highest priority, therefore we are taking
these steps to mitigate the impact of COVID-19 at Obalon retail
facilities,” said Bill Plovanic, President and Chief Executive
Officer of Obalon. “Although we have not received any reports of
our patients, employees or providers testing positive for the novel
coronavirus, or being symptomatic, we believe suspending sales to
potential new patients is the best course of action at this time
given the elective nature of our treatment program. During this
time of unprecedented economic uncertainty, we will also pause
activities related to our plans to expand the number of additional
retail treatment centers and reassess when conditions improve.”
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. For more information, please
visit http://www.obalon.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements that are
not purely historical regarding Obalon’s or its management’s
intentions, beliefs, expectations and strategies for the future,
including those related to new products and their potential
benefits. All forward-looking statements and reasons why results
might differ included in this press release are made as of the date
of this release, based on information currently available to
Obalon, deal with future events, are subject to various risks and
uncertainties, and actual results could differ materially from
those anticipated in those forward looking statements. The risks
and uncertainties that may cause actual results to differ
materially from Obalon’s current expectations are more fully
described in Obalon’s annual report on Form 10-K for the period
ended December 31, 2019 and its other reports, each as filed with
the Securities and Exchange Commission. Except as required by law,
Obalon assumes no obligation to update any such forward-looking
statement after the date of this report or to conform these
forward-looking statements to actual results.
For Obalon Therapeutics, Inc.
Investor Contact: Bill Plovanic President and Chief
Executive Officer Obalon Therapeutics, Inc. Office: +1
760 607 5103 wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Oct 2023 to Oct 2024